RxDoctor Payments DataLook up a doctor →

Benjamin Bridges, MD

Hematology & Oncology · Annapolis, MDNPI 1477694420

Payments from drug & device makers

$180,755in general payments, 2019–2025

Across 240 payments — averaging $753.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$88K
  • Merck$42K
  • Pfizer$36K
  • AbbVie$11K
  • AstraZeneca$433
  • Novartis$316
  • plus $3K from 54 others
$940in research payments, 2019–2025

Across 1 payment — averaging $940.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$940

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly3$87,534
Merck25$41,823
Pfizer25$35,996
AbbVie20$11,325
AstraZeneca(2 entities)14$433
Novartis15$316
Daiichi Sankyo Inc.9$251
Johnson & Johnson9$234
GSK7$196
Bristol Myers Squibb6$187
Incyte Corporation7$149
E.r. Squibb & Sons, L.L.C.6$148
Astellas Pharma US Inc5$124
Intera Oncology, Inc1$114
AVEO Pharmaceuticals, Inc.3$98
Lilly USA, LLC5$97
Gilead5$95
Genentech USA, Inc.5$89
Eisai Inc.4$83
Bayer3$76
Beone Medicines USA, Inc.3$66
Amgen3$65
Syndax Pharmaceuticals, Inc.2$65
Coherus Oncology, Inc.3$60
Legend Biotech USA Inc.2$58
Puma Biotechnology, Inc.3$57
Ipsen Biopharmaceuticals, Inc2$54
Boehringer Ingelheim2$48
Seagen Inc.2$44
Takeda Pharmaceuticals U.S.A., Inc.2$40
Sumitomo Pharma America, Inc.2$39
Deciphera Pharmaceuticals Inc.2$38
Sanofi2$38
Pharmacosmos Therapeutics Inc.2$38
Tersera Therapeutics LLC1$37
Invivyd Inc1$35
Pharmacyclics LLC, An Abbvie Company2$34
Jazz Pharmaceuticals Inc.1$32
Pharmaessentia USA Corporation1$32
Clinigen, Inc.2$30
Taiho Oncology, Inc.1$30
Acrotech Biopharma Inc.2$28
Tolmar, Inc.1$28
Pharmaand GmbH1$28
Array Biopharma Inc1$27
Tesaro, Inc.1$26
Lundbeck LLC1$26
Dendreon Pharmaceuticals LLC1$23
Kyowa Kirin, Inc.1$23
Dova Pharmaceuticals1$22
Spectrum Pharmaceuticals Inc.1$22
Mylan Institutional Inc.1$22
Bioprotect Medical, Inc.1$21
Regeneron Healthcare Solutions, Inc.1$21
Blueprint Medicines Corporation1$21
Aurobindo Pharma USA, Inc.1$20
Sobi, Inc1$19
Adaptive Biotechnologies Corporation1$17
Alnylam Pharmaceuticals Inc.1$16
Exelixis Inc.1$14

How this compares

$180,755 in reported general payments places this provider in the 75th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$4,075,498
Medicare patients
2,406
Services billed
163,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Annapolis

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →